List of Excipients in Branded Drug DOCETAXEL

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Hospira Inc	DOCETAXEL	docetaxel anhydrous	0409-0201	ALCOHOL
Hospira Inc	DOCETAXEL	docetaxel anhydrous	0409-0201	CITRIC ACID MONOHYDRATE
Hospira Inc	DOCETAXEL	docetaxel anhydrous	0409-0201	POLYETHYLENE GLYCOL 300

Generic Drugs Containing DOCETAXEL

Company	Ingredient	NDC	Excipient
Hikma Pharmaceuticals USA Inc	docetaxel	0143-9204	ALCOHOL
Hikma Pharmaceuticals USA Inc	docetaxel	0143-9204	ANHYDROUS CITRIC ACID
Hikma Pharmaceuticals USA Inc	docetaxel	0143-9204	POLYSORBATE 80

What are the Most Frequently-Used Excipients in DOCETAXEL?

# Of NDCs	Excipient
24	ALCOHOL
24	ANHYDROUS CITRIC ACID
1	CITRIC ACID MONOHYDRATE

Docetaxel Excipient Strategy and Commercial Opportunities

Last updated: September 29, 2026

Docetaxel is an established taxane with broad generic competition and limited protection from the original active-ingredient patent estate. Commercial opportunity has shifted from conventional docetaxel supply to differentiated delivery systems that reduce polysorbate 80 exposure, eliminate ethanol, improve infusion handling, increase tumor exposure, or enable nonintravenous administration.

The strongest near-term opportunity is a ready-to-use or low-excipient intravenous formulation with demonstrated equivalence, low infusion burden, and hospital-use advantages. Longer-term opportunities include nanoparticle, liposomal, oral, depot, and tumor-targeted formulations. These products can obtain commercial protection through formulation, manufacturing, method-of-use, and device claims, although clinical development requirements rise sharply with formulation complexity.

What excipients are used in approved docetaxel products?

Approved conventional docetaxel products generally use polysorbate 80 and ethanol to solubilize the poorly water-soluble active ingredient. The formulation is diluted before intravenous infusion.

Product characteristic	Conventional docetaxel approach
Active ingredient	Docetaxel, commonly as docetaxel anhydrous
Primary solubilizer	Polysorbate 80
Co-solvent	Ethanol in many concentrate presentations
Diluent	0.9% sodium chloride or 5% dextrose, depending on product labeling
Administration	Intravenous infusion
Main formulation issue	Hypersensitivity, infusion reactions, foam, extractables, and handling complexity
Commercial status	Mature generic market with multiple manufacturers

The Taxotere labeling identifies polysorbate 80 and ethanol as formulation components and includes warnings related to hypersensitivity reactions and alcohol exposure.[1] Generic products may have different excipient quantities and presentation formats, but they remain subject to pharmaceutical equivalence, quality, stability, and labeling requirements under the abbreviated new drug application pathway.

Polysorbate 80 is effective but creates several development and commercial concerns:

• It can generate peroxide and other degradation products during storage.
• It may contribute to hypersensitivity and infusion reactions.
• It can produce foam during preparation and handling.
• It can interact with tubing, filters, containers, and other formulation components.
• It may affect free-drug exposure through micellar solubilization.
• It increases the regulatory burden for impurity control and container compatibility.

Ethanol creates a separate set of concerns. Its presence can matter for pediatric patients, patients with alcohol-use restrictions, patients receiving multiple solvent-containing medicines, and institutions seeking simpler infusion protocols. Ethanol also creates flammability, labeling, occupational handling, and dose-volume considerations.

What excipient strategy is best for generic docetaxel?

For a conventional generic, the preferred strategy is usually a low-risk polysorbate 80 formulation that matches the reference product’s critical quality attributes without introducing unnecessary excipient novelty.

Conventional polysorbate 80 formulation

This route has the lowest development risk because the active ingredient, route, dosage form, and clinical use are established. Key controls include:

• Polysorbate 80 grade and impurity profile
• Peroxide value and oxidative degradation
• Docetaxel assay and related substances
• Particle formation after dilution
• Container closure integrity
• Adsorption to infusion bags and tubing
• Dilution stability and in-use hold time
• Visible and subvisible particulate levels
• Infusion-line compatibility
• Sterility and endotoxin control

A generic manufacturer can still compete through lower cost, smaller vial sizes, simplified packaging, improved stability, or supply reliability. The formulation itself is unlikely to create substantial exclusivity unless the product contains a novel excipient combination or achieves a clinically meaningful handling or safety advantage.

Ethanol-free formulation

An ethanol-free formulation can target hospitals that want to avoid alcohol-containing chemotherapy preparations. The technical challenge is maintaining docetaxel solubility and preventing precipitation after dilution.

Potential excipient classes include:

• Nonionic surfactants other than polysorbate 80
• Polyoxyl castor oils
• Poloxamers
• Cyclodextrins
• Lipid-based solubilizers
• Phospholipid systems
• Mixed micellar systems
• Solvent-free nanoparticles

Each replacement introduces a different toxicology and regulatory profile. Removing ethanol while retaining polysorbate 80 may simplify handling but does not eliminate surfactant-related concerns. Replacing both ethanol and polysorbate 80 is more commercially differentiated but requires greater characterization of pharmacokinetics, immunogenicity-related reactions, infusion tolerability, and stability.

Low-polysorbate formulation

A low-polysorbate formulation can be positioned as a tolerability and preparation improvement rather than a new docetaxel product. The commercial case is strongest when the formulation demonstrates one or more of the following:

• Lower incidence of acute infusion reactions
• Reduced need for premedication
• Less foam during preparation
• Longer post-dilution stability
• Reduced adsorption or precipitation
• Lower administration volume
• More convenient storage or transport

A formulation that merely changes polysorbate concentration without clinical or operational benefit may face weak differentiation and limited pricing power.

What formulation patents can protect docetaxel products?

Docetaxel formulation patents generally focus on the composition, delivery system, preparation method, or therapeutic use rather than the active molecule itself.

Patent claim categories

Claim category	Potential protected subject matter	Commercial value
Composition	Docetaxel with defined surfactant, co-solvent, lipid, polymer, or complexing agent	High if difficult to design around
Particle system	Nanoparticles, nanocrystals, liposomes, micelles, or polymeric carriers	High when supported by clinical benefit
Stability	Defined impurity limits, pH range, particle-size distribution, or storage conditions	Moderate
Manufacturing	Mixing, homogenization, drying, filtration, sterilization, or lyophilization processes	Moderate to high
Administration	Infusion rate, dose schedule, premedication reduction, or administration sequence	Variable
Method of use	Cancer indication, combination therapy, patient selection, or biomarker-defined use	Variable
Device	Prefilled syringe, closed-system transfer, infusion container, or reconstitution system	Moderate

The strongest patent estate usually combines composition claims with manufacturing and method-of-use claims. A narrow composition claim may be vulnerable if competitors can substitute another solubilizer or alter concentration. Process claims are often useful for protecting complex nanoparticle or liposomal systems but may be difficult to enforce without access to manufacturing evidence.

How strong is the patent estate for conventional docetaxel?

The conventional docetaxel estate is weak as a barrier to generic entry because the original active-ingredient and core product protections have expired in major markets. Docetaxel generics are commercially established in the United States and other regulated markets.

A new formulation can create a separate patent position, but the scope depends on whether the product has:

1. A genuinely novel composition.
2. Reproducible and clinically relevant performance.
3. Claims that competitors cannot readily avoid.
4. Regulatory exclusivity independent of patent protection.
5. Manufacturing steps that are difficult to reverse engineer.
6. A target market willing to pay for the improvement.

Patent applicants should avoid relying only on broad claims to “docetaxel nanoparticles” or “docetaxel with a surfactant.” Such claims may face novelty, obviousness, enablement, written-description, and anticipation challenges. Better protection often comes from defined particle-size ranges, surface characteristics, drug-loading parameters, release profiles, impurity limits, or validated process conditions.

What FDA regulatory pathways apply to differentiated docetaxel formulations?

The pathway depends on whether the product is pharmaceutically equivalent to an approved injectable or materially changes the formulation and exposure profile.

ANDA pathway

An ANDA is appropriate for a product that meets the requirements for generic equivalence to a reference-listed drug. The applicant generally must demonstrate pharmaceutical equivalence and bioequivalence or satisfy applicable product-specific requirements.

This pathway is best suited to:

• Conventional docetaxel injection
• Alternative vial sizes
• Comparable polysorbate 80 formulations
• Products with the same route and dosage form
• Products that do not introduce meaningful clinical differences

An ANDA is less suitable for a nanoparticle or liposomal formulation that materially changes pharmacokinetics, tissue distribution, or administration characteristics.

505(b)(2) pathway

A 505(b)(2) application is more suitable for a reformulated docetaxel product that relies partly on existing FDA findings but introduces a new formulation, delivery system, route, dosing regimen, or clinical use.

Potential 505(b)(2) products include:

• Ethanol-free docetaxel
• Reduced-polysorbate docetaxel
• Liposomal docetaxel
• Albumin-bound or polymeric docetaxel
• Long-acting injectable docetaxel
• Oral docetaxel
• Tumor-targeted docetaxel

The sponsor may need clinical pharmacology, comparative safety, infusion-reaction data, and efficacy data depending on the extent of formulation change. FDA may require clinical studies when the new formulation changes exposure or is intended to improve safety rather than merely replicate the reference product.

FDA exclusivity

Docetaxel itself is not eligible for biosimilar exclusivity because it is a small-molecule drug, not a biologic. A new formulation could potentially obtain:

• Five-year new chemical entity exclusivity if it qualifies as a new active moiety, which a docetaxel reformulation generally would not.
• Three-year exclusivity for a new clinical investigation essential to approval.
• Orphan-drug exclusivity if the product qualifies for an orphan indication.
• Pediatric exclusivity if statutory requirements are met.
• Patent-based protection through approved formulation or method-of-use claims.

A standard reformulation should not be valued as though it receives full new chemical entity exclusivity.

What is the Orange Book status of docetaxel?

The Orange Book identifies approved reference-listed and generic drug products, therapeutic equivalence evaluations, and certain patent and exclusivity information.[2] Conventional docetaxel injection products have been subject to generic approval and substitution in the U.S. market.

For a new docetaxel formulation, Orange Book strategy depends on the approved application:

• A conventional ANDA product typically relies on the reference-listed drug and may have limited product-specific patent value.
• A 505(b)(2) product may list patents covering the formulation, method of use, or delivery system.
• Listed patents can trigger Paragraph IV litigation if an ANDA applicant certifies that the patent is invalid, unenforceable, or not infringed.
• Method-of-use patents may be carved out from labeling if FDA permits a section viii statement.

The commercial relevance of an Orange Book listing depends on claim breadth, remaining patent term, the likelihood of a Paragraph IV challenge, and whether the product’s label can be designed around the claimed use.

When does docetaxel lose exclusivity, and what generic-entry risks exist?

The original docetaxel exclusivity period has expired in the United States. Generic entry is therefore a current market condition, not a future event.

Exclusivity element	Docetaxel position
Active-ingredient exclusivity	Expired
Original conventional formulation protection	Expired or commercially ineffective against established generics
Conventional generic entry	Established
Biosimilar competition	Not applicable
Paragraph IV relevance	Relevant to new formulation patents and any remaining listed patents
Main current barrier	Manufacturing quality, supply reliability, formulation performance, and regulatory execution

Generic entry risks for a new formulation include:

• ANDA applicants using a different excipient system.
• Section viii carve-outs for method-of-use claims.
• Invalidity challenges to formulation patents.
• Noninfringement based on different particle sizes or excipient concentrations.
• Paragraph IV challenges soon after patent listing.
• Hospital substitution pressure if the product is therapeutically equivalent.
• Payers treating the formulation as interchangeable with low-cost conventional docetaxel.

A differentiated product has stronger protection when its commercial value depends on a measurable clinical attribute that is difficult to reproduce through a simple formulation change.

Which excipient platforms offer the best commercial opportunities?

Nanoparticle and nanocrystal systems

Nanoparticle formulations can improve apparent solubility, alter distribution, and reduce reliance on conventional surfactants. They can also enable concentrated formulations or modified release.

Potential benefits include:

• Reduced polysorbate 80 exposure
• Lower or absent ethanol content
• Improved tumor exposure
• Controlled drug release
• Higher drug loading
• Potentially shorter infusion time

Risks include aggregation, sterilization difficulty, particle-size drift, scale-up complexity, and more demanding clinical pharmacology. Manufacturing know-how can provide meaningful protection if the process is difficult to replicate.

Liposomal docetaxel

Liposomes can reduce free-drug exposure and alter tissue distribution. The formulation may support a safety-oriented positioning strategy, particularly if it reduces acute hypersensitivity, neuropathy, or off-target exposure.

Commercial success depends on proving that the liposomal product offers a meaningful advantage over inexpensive conventional docetaxel. A modest pharmacokinetic difference without better clinical outcomes is unlikely to support premium pricing.

Albumin-bound or protein-associated systems

Protein-associated docetaxel products may seek to replicate some commercial attributes of albumin-bound paclitaxel, including reduced dependence on solvent systems. The approach requires careful control of protein-drug binding, particle structure, aggregation, sterility, and release.

The competitive challenge is substantial because the product would face comparison with both conventional docetaxel and established nanoparticle taxanes.

Oral docetaxel

Oral delivery has the largest convenience potential but the highest development risk. Docetaxel has poor oral bioavailability because of low solubility, intestinal metabolism, and efflux transport. Formulations may require:

• Lipid-based excipients
• Self-emulsifying drug-delivery systems
• Permeation enhancers
• P-glycoprotein inhibitors
• Enzyme inhibitors
• Nanoparticles or amorphous dispersions

The inclusion of absorption enhancers can create drug-interaction, toxicity, and regulatory issues. An oral product may require a full clinical development program and could compete more directly with oral chemotherapy products than with generic intravenous docetaxel.

Depot and local delivery

Intratumoral, implantable, or long-acting docetaxel systems could target localized cancers or surgical beds. Candidates include biodegradable polymers, hydrogels, microspheres, and implantable matrices.

These products may support composition, device, and method-of-use patents. Their market is narrower, and clinical development must demonstrate local benefit, reproducible dosing, and acceptable tissue tolerability.

How does docetaxel compare with paclitaxel for excipient strategy?

Docetaxel and paclitaxel both face solvent-related formulation issues, but their competitive landscapes differ.

Attribute	Docetaxel	Paclitaxel
Conventional solvent concern	Polysorbate 80 and, for some products, ethanol	Cremophor EL and ethanol in conventional products
Major differentiated platform	Nanoparticle, liposomal, oral, and low-surfactant systems	Albumin-bound paclitaxel and other solvent-reduced systems
Generic competition	Broad	Broad
Biosimilar pathway	Not applicable	Not applicable
Main commercial challenge	Demonstrating value over inexpensive generic infusion	Competing with established solvent-free nanoparticle paclitaxel
Strongest opportunity	Lower-excipient and operationally simpler infusion	Specific safety, dosing, or delivery advantages

Docetaxel has an opportunity to occupy a solvent-reduction position, but the product must avoid becoming a copy of an existing nanoparticle taxane. Differentiation should focus on lower infusion burden, improved tolerability, reduced preparation complexity, or a specific tumor setting.

Which companies are challenging conventional docetaxel, and what is the competitive landscape?

The conventional market includes branded and generic manufacturers supplying intravenous docetaxel. Major generic oncology suppliers have competed through price, hospital contracting, manufacturing capacity, and supply continuity rather than novel excipient technology.

The more important competitive set for a reformulated product includes:

• Generic docetaxel injection suppliers
• Nanoparticle taxane developers
• Liposomal oncology companies
• Manufacturers of ready-to-use injectable products
• Contract development and manufacturing organizations with sterile nanoparticle capability
• Companies developing oral taxanes and absorption-enhanced formulations

A new entrant should expect conventional docetaxel to remain the price benchmark. Any premium product must show a reduction in total treatment cost, not only an improved laboratory formulation. Relevant economic endpoints include preparation time, pharmacy labor, premedication use, infusion-chair time, hypersensitivity management, waste, and hospitalization associated with adverse events.

What licensing and partnership opportunities exist for docetaxel excipients?

Licensing opportunities are strongest in enabling technologies rather than in docetaxel itself. Relevant assets include:

• Proprietary surfactant or co-solvent systems
• Sterile nanoparticle manufacturing platforms
• Liposomal encapsulation technology
• Oral absorption-enhancement systems
• Long-acting biodegradable depots
• Closed-system infusion and ready-to-use packaging
• Excipient combinations with established toxicology packages
• Analytical methods for particle size, free drug, and degradation products

A practical deal structure may combine an excipient-platform license with regional development rights, milestone payments tied to formulation selection and FDA filing, and royalties based on net sales. The licensor’s value is highest when the excipient system has prior parenteral use, a strong regulatory file, scalable manufacturing, and defensible composition or process patents.

What manufacturing and IP barriers affect commercial entry?

Sterile manufacturing is a greater barrier than active-ingredient access. A formulation may be chemically simple but commercially difficult if it requires:

• High-pressure homogenization
• Aseptic nanoparticle processing
• Specialized filtration
• Low-shear filling
• Tight particle-size control
• Oxygen exclusion
• Light protection
• Specialized container closure systems
• Complex in-use stability testing

Manufacturing patents can protect process parameters, but process protection should be paired with composition claims. Trade secrets may protect scale-up conditions, mixing order, shear rate, temperature profile, and sterilization controls. Those trade secrets are useful only when the finished product cannot readily reveal the process.

What are the most attractive docetaxel product strategies?

Strategy	Regulatory burden	Differentiation	Patent potential	Commercial outlook
Conventional generic injection	Low to moderate	Low	Low	Price and supply competition
Ethanol-free injection	Moderate	Moderate	Moderate	Good if handling or tolerability improves
Low-polysorbate injection	Moderate	Moderate	Moderate	Dependent on clinical proof
Ready-to-use bag or syringe	Moderate	Moderate	Moderate	Attractive for hospital workflow
Nanoparticle docetaxel	High	High	High	Potential premium, high trial risk
Liposomal docetaxel	High	High	High	Requires meaningful safety or efficacy benefit
Oral docetaxel	High	High	High	Large convenience opportunity, substantial risk
Depot or local delivery	High	High	High	Niche indications and specialist adoption

The best risk-adjusted opportunity is an ethanol-free, reduced-polysorbate, ready-to-use intravenous product supported by strong stability, compatibility, and infusion-tolerability data. The highest-value opportunity is an oral or nanoparticle product, but it requires substantially greater clinical investment and faces stronger competition from existing taxane technologies.

Key Takeaways

• Conventional docetaxel uses polysorbate 80 and, in many presentations, ethanol.
• The original docetaxel patent estate no longer prevents generic competition.
• A conventional generic strategy is commercially viable but offers limited differentiation.
• Ethanol-free and reduced-polysorbate formulations have the best near-term balance of risk and opportunity.
• Nanoparticle, liposomal, oral, and depot systems offer stronger patent potential but require more extensive clinical development.
• Docetaxel is a small molecule, so biosimilar competition is not relevant.
• ANDA development is appropriate for conventional equivalent products; 505(b)(2) is more suitable for materially differentiated formulations.
• Formulation patents should be supported by manufacturing and method-of-use claims.
• Hospital economics, infusion workflow, and supply reliability are as important as excipient novelty.
• A premium product must demonstrate a measurable clinical or operational advantage over low-cost generic docetaxel.

FAQs

Can polysorbate 80 be removed from docetaxel completely?

Yes, but removal requires another solubilization or delivery platform. Nanoparticles, liposomes, cyclodextrin systems, lipid formulations, and alternative surfactants are possible approaches. The replacement must meet parenteral safety, stability, sterility, and dilution requirements.

Is ethanol-free docetaxel eligible for a new patent?

Potentially. Patentability depends on the specific excipient combination, concentration ranges, stability profile, manufacturing process, and demonstrated technical effect. A simple substitution of one known solvent for another may face obviousness challenges.

Does docetaxel require biosimilar analysis?

No. Docetaxel is a chemically synthesized small-molecule drug. Competitive analysis should focus on ANDA generics, 505(b)(2) reformulations, formulation patents, and therapeutic equivalence.

Can an oral docetaxel product rely on the existing intravenous approval?

It may rely partly on existing FDA findings through a 505(b)(2) application, but oral delivery changes bioavailability, exposure, safety, and administration. Clinical pharmacology and potentially efficacy studies would be expected.

What is the main commercial weakness of a new docetaxel formulation?

The main weakness is the low price of conventional generic docetaxel. A new formulation must produce a clear benefit in safety, administration, treatment duration, patient convenience, or total healthcare cost to support premium pricing.

References

1. Sanofi-Aventis U.S. LLC. (2023). Taxotere (docetaxel) injection concentrate prescribing information. U.S. Food and Drug Administration.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.

3. U.S. Food and Drug Administration. (2024). Abbreviated new drug application submissions: Guidance for industry. U.S. Department of Health and Human Services.

4. U.S. Food and Drug Administration. (2024). Applications covered by section 505(b)(2): Guidance for industry. U.S. Department of Health and Human Services.

5. U.S. Food and Drug Administration. (2023). Inactive ingredient database. U.S. Department of Health and Human Services.

6. Sparreboom, A., van Tellingen, O., Nooijen, W. J., & Beijnen, J. H. (1998). Preclinical pharmacokinetics of paclitaxel and docetaxel. Anti-Cancer Drugs, 9(1), 1-9.

7. ten Tije, A. J., Verweij, J., Loos, W. J., & Sparreboom, A. (2003). Pharmacological effects of formulation vehicles: Implications for cancer chemotherapy. Clinical Pharmacokinetics, 42(7), 665-685.